Abstract-We investigated the effect of pyridoxal-5'-phosphate (PALP) on tobra mycin (TOB)-induced nephrotoxicity in rats. Paper electrophoretic analysis showed that in the mixture of TOB and PALP, the spot corresponding to TOB alone almost disappeared and the spot associated with TOB overlapped with that associated with PALP, although the spots of TOB alone and PALP alone were observed as single spots on the cathode and anode sides, respectively. The overlapping of both compounds indicated that TOB could directly interact with PALP in vitro. In the assay of TOB binding to renal brush border membranes (BBMs), PALP significantly inhibited the binding of TOB to BBMs by interacting with TOB outside of BBMs vesicles.
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Intrarenal TOB levels in rats receiving TOB and PALP were lower than those in rats given TOB alone.
Combination with PALP markedly suppressed the urinary protein content, urinary N-acetyl-(3-D glucosaminidase activity and blood urea nitrogen content elevated by TOB, and also reduced the degree of TOB-induced renal tubular cell necrosis. These results indicate that PAL P protects the rat kidneys from TOB-induced nephrotoxicity and that the protective effect of PALP may be due to the reduced intrarenal TOB con centration and less binding of TOB to BBMs induced by the interaction of PALP with TO B.
We have already reported that latamoxef (LMOX), an oxacephem antibiotic, prevents tobramycin (TOB)-induced nephrotoxicity in rats and that the protective effect of LMOX is partly due to the ability of LMOX to reduce the intrarenal TOB concentration (1) . We have found that the inhibitory effect of LMOX on intrarenal TOB level resulted from the inhi bition of the binding of TOB to renal brush border membranes (BBMs) (2) by a molecu lar interaction between TOB and LMOX (3) .
From our previous study using LMOX, it was hypothesized that a compound which has a negative charge in its molecule and is excreted into the urine might prevent TOB induced nephrotoxicity by reducing the in trarenal TOB level and by inhibiting the bind ing of TOB to BBMs through a molecular interaction between TOB and the compound.
As shown in Fig. 1 , pyridoxal-5'-phosphate (PALP), an active form of vitamin B6, has a phosphate group in its molecule and is nega tively charged at physiological pH. PALP also has an aldehyde group, which can form a Schiff base by binding covalently to amino groups of TOB. In general, excess amounts of vitamins are excreted into the urine without converting them into metabolites, when large amounts of vitamins are administered. There fore, in the present study, to examine the ability of PALP to prevent TOB-induced nephrotoxicity, we designed experiments to monitor the following: 1) in vitro interaction of TOB with PALP, 2) the effect of PALP on TOB binding to BBMs, 3) the effect of PALP on intrarenal TOB concentration, and 4) the effect of PALP on the nephrotoxicity of TOB in vivo.
In addition, in order to obtain some in formation about the mechanism of the action of PALP on the interaction with TOB and the TOB binding to BBMs, pyridoxal (PL) and pyridoxine (PN), the precursor of PALP, and 4-pyridoxic acid (4-PA), a metabolite of PALP, were examined.
Materials and Methods
Drugs: TOB was provided by Shionogi Co., Ltd. (Osaka, Japan). PALP, PL and PN were purchased from Tokyo Kasei (Tokyo, Japan), and 4-PA was obtained from Sigma Chemi cals (St. Louis, MO, U.S.A.).
Animals: Male Sprague-Dawley rats weighing 230 g (Shizuoka Laboratory Animal Center, Shizuoka, Japan) were used in all experiments. These animals were housed in an air-conditioned room at 24±1 °C. Paper electrophoretic analysis: According to our previously reported method (3), paper electrophoresis analysis was used to clarify whether PALP interacts with TOB in vitro. Briefly, TOB alone, PALP alone and a mixture of both drugs (molar ratio, TOB:LMOX=1 :2) were dissolved in H2O, and the pH was adjusted to 7.4 by the addition of HCI or NaOH. Each solution containing drugs was incubated for 10, 30 and 60 min at 37'C, and aliquots sampled at a suitable time were subjected to paper electrophoresis.
The spots associated with TOB and PALP on the paper were visualized by the ninhydrin reaction and ultraviolet irradiation (A=254 nm), respec tively. In addition, the mixtures of TOB and PL, PN or 4-PA were also analyzed.
Assay of TOB binding to BBMs: The assay of TOB binding to BBMs, which were isolated from rat kidney cortex by the method of Ca precipitation (4, 5) , was carried out using the method of Ishikawa et al. (6) . In brief, in a general assay, 200 el of membrane suspen sion (200-250 ag protein) was incubated at 37 °C for 10 min with 200 ,aI of 0.2 mM of TOB in 20 mM HEPES/Tris buffer (pH 7.4) con taining 100 mM mannitol, followed by centrifugation at 45,000 x g for 30 min at 4"C. After removal of the supernatant, 200 ,ul of H2O and 5% trichloroacetic acid were added, centrifuged at 1,600xg for 20 min, and the resultant supernatant was used for measuring TOB concentration.
The TOB concentration was determined by means of substrate labeled fluorescent immunoassay (SLFIA, Ames TDA tobramycin assay kit, Miles Sankyo Co. Ltd., Toyo, Japan) (7). The final concentrations of 0.2 mM of TOB and 0.4, 0.8, 2 or 4 mM of PALP were used for the binding assay. According to the binding assay de scribed above, we designed experiments to determine the following: 1) effect of simul taneous treatment and pretreatment with PALP on TOB binding to BBMs; 2) effect of the reaction mixture of TOB and P.ALP, which was preincubated for 3 hr at 37'C to make a complex of both compounds, on TOB binding to BBMs; and 3) the binding of TOB to PALP treated and non-treated BBMs. The effects of PL, PN and 4-PA on TOB binding to BBMs also were examined using the same concen trations as those of PALP.
Measurement of the intrarenal TOB con centration: Drug treatments were designed as follows: 1) Rats were given TOB (90 mg/kg/ day, s.c.) alone or TOB and PAL.P (200 mg/ kg, p.o. 1 hr before TOB injection) for 3 days: 2) TOB (70-150 mg/kg, s.c.) alone or TOB and PALP (156-333 mg/kg, p.o. 1 hr before TOB injection) were administered to rats; and 3) Treatments with PALP (200 mg/kg, p.o.) to rats were performed 5 and 1 hr before and after single s.c. injection of TOB as well as simultaneously with TO B treatments. Twenty four hours after the drug administration, the left kidneys were removed and the intrarenal TOB concentration was determined by the previously reported method (1), except for centrifugation at 9,000 x g for 15 min and the measurement of TOB concentration by SLFIA.
In vivo nephrotoxicity studies: 1) Drug treatment: Animals were given daily s.c. doses of TOB (90 mg/kg) alone or TOB and p.o. doses of PALP (200 or 510 mg/kg) for 15 consecutive days. Daily p.o. administrations of PALP were carried out 1 hr before the TOB injection.
2) Measurements of urinary protein content and N-acetyl-(3-D-glucosaminidase (NAG) activity, and blood urea nitrogen (BUN) content: After the beginning of drug treat ment, the twenty-four hour urine was col lected at suitable intervals, and blood was obtained from the jugular vein on the 1 5th day. Urinary protein content and NAG activity, as well as BUN content, were measured as in our previous report (1) . In addition to the measurements of biochemical parameters in the urine and blood, the histological observa tion of kidneys also was performed on the sections stained with Periodic Acid-Schiff (PAS) for light microscopy, as described pre viously (1 ) .
Statistical analysis: The data were sub jected to one-way analysis of variance and the Duncan multiple range test or non-parametric statistics. When only two groups were used, the data were analyzed by Student's t-test. The data in the text and figures are expressed as the mean±S.D.
Differences were con sidered significant if the P value was ;0.05.
Results

Analysis of interaction of TOB and PALP by paper electrophoresis
As shown in Fig. 2A , spots of TOB and PALP were observed as single spots on the cathode and anode side, respectively. When the solutions containing TOB and PALP were incubated at 37 °C for various time, the spot corresponding to TOB alone almost disap peared, and the spot associated with TOB overlapped with that associated with PALP from the cathode to anode side. The degree of the overlap seemed to become greater as in cubation time increased. The increase in the molar ratio of PALP to TOB accelerated the degree of the interaction between both com pounds (data not shown).
Additionally, when the mixture of TOB and PL was analyzed by paper electrophoresis, the spot associated with TOB overlapped with that associated with PL on the cathode side, indicating that PL also directly interacted with TOB. However, the degree of the interaction between these compounds seemed to be less than that observed between TOB and PALP. In the mixture of TOB and PN, only an altera tion of the mobility of PN on the paper was detected, and 4-PA showed no interaction with TOB (Fig. 2B ).
Assay of TOB binding to BBMs
As shown in Fig. 3A , the simultaneous ad dition of TOB (0.2 mM) and PALP (0.4 to 4 mM) to the BBMs fraction significantly inhib ited TOB binding to BBMs by about 20 to 90%. The addition of the reaction mixture of TOB and PALP (0.8 to 4 mM), which was preincubated for 3 hr at 37'C, resulted in less binding of TOB to BBMs than that observed in the case of simultaneous addition of both drugs (Fig. 3B) . Pretreatment of BBMs with PALP, except in the case of an 0.8 mM dose of PALP, did not result in less binding of TOB to BBMs, as compared with the results from the simultaneous addition of both compounds. It was of interest that the pretreatment with 0.8 mM of PALP resulted in increased TOB binding to BBMs. (Fig. 3C) . Each mixture of TOB and other compounds (molar ratio, TOB:compound=l :2) was incubated for 10, 30 and 60 min at 37'C. At a suitable time, aliquots were subjected to paper (2.5 x 1 5 cm) electrophoresis for 90 min with 70 mM Tris-HCI buffer (pH 7.4). T+PALP, PL, PN or 4-PA: in cubated mixture. #: the drugs were separately spotted at the origin. T: tobramycin.
0.: origin. Figure 3D shows that no significant dif ferences in the TOB binding to the mem branes were observed between PALP-treated and non-treated BBMs.
We also studied the cause of the increase in TOB binding to BBMs observed in the case of pretreatment with 0.8 mM of PALP. As shown in Fig. 4A , the pretreatment with 0.6, 1.0 and 1.2 mM of PALP as well as with 0.8 mM of PALP clearly resulted in increases in TOB binding to the membranes, as compared with simultaneous treatment with both com pounds. The inhibitory effect of PALP (0.8 mM) on TOB binding to BBMs disappeared as the preincubation time of PALP and BBMs increased (Fig. 4B) . The decrease in the medium osmolarity, which promotes the transport of PALP into BBM vesicles, weak ened the inhibitory effect of PALP on TOB binding to BBMs (Fig. 4C) .
In addition, PL, PN and 4-PA were ineffec tive in inhibiting the binding of TOB to BBMs (data not shown). 3. Effect of PALP on intrarenal TOB con centration As shown in Fig. 5A , when TOB (90 mg/ kg/day, s.c.) alone was given to rats, the intrarenal TOB concentrations were 162.6± In addition, each combination of TOB (70-150 mg/kg, s.c.) and PALP (156-333 mg/kg, p.o.), in which the molar ratios JOB: PALP=1 :4) of TOB to PALP were the same, resulted in almost the same inhibitory rate (about 34%) on the intrarenal concentration of TOB (Fig. 5B) . Figure 5C shows the effect on the renal TOB level of PALP administered at a different time from that of the TOB injection. The treatment with PALP simul taneously and 1 hr before the TOB injection resulted in significant suppression of the TOB level in the kidney, whereas no significant differences in the intrarenal TOB concen tration were observed in the treatment with PALP at 5 hr before, 5 hr after, or 1 hr after TOB injection. 4. In vivo nephrotoxicity study 1) Effect of TOB alone and in combination with PALP on biochemical parameters in urine and blood: Figure 6 illustrates the effect of TOB alone and in combination with PALP on urinary protein content, NAG activity, and BUN content. TOB alone increased urinary protein content and NAG activity, which peaked on the 7th day and returned to nearly normal levels by the 1 5th day. On the other hand, combination of TOB and PALP signifi cantly suppressed the increases in urinary protein content and NAG activity induced by TOB alone by about 90%. Likewise, on the 15th day, the BUN content in rats given TOB alone was higher by about 80% than the value in the normal group, whereas the BUN con tent increased by TOB was markedly sup pressed by combination with PALP.
2) Histological observations: On the 7th day, the kidney from rats receiving TOB alone showed severe tubular cell necrosis and ex posure of tubular basement membrane (Fig.  7A) . However, as shown in Fig. 7B and C, the combination with PALP markedly reduced the degree of cell necrosis induced by TOB. 
Discussion
The purpose of the present study was to examine the ability of PALP to prevent TOB induced nephrotoxicity.
In the paper electrophoretic analysis, we demonstrated that PALP directly interacted with TOB in vitro, and this was in agreement with the results in our previous study using LMOX (3) .
To obtain information about the mechanism of the molecular interaction between TOB and PALP, we examined whether PL, PN and 4 PA are able to interact with TOB in vitro. The inability of PN to interact with TOB suggested that phosphate and aldehyde groups in PALP play a role in the molecular interaction of PALP with TOB. The paper electrophoretic analysis using PL suggests that the aldehyde group of PALP, at least in part, contributes to the interaction between PALP and TOB. Keniston (8) reported that polyamines inter acted with PALP, and the interaction was due to the formation of a Schiff base between the amino groups of the polyamine and the alde hyde group of PALP. Thus, a Schiff base formed from the amino group of TOB and the aldehyde group of PALP may be involved in the molecular interaction between TOB and PALP. Likewise, PL also may interact with TOB through the formation of a Schiff base, because at 37°C, PL could induce an elimi nation reaction of serine 3-phosphate to inorganic phosphate, pyruvate and ammonia, which was mediated by the formation of a Schiff base between the amino group of serine 3-phosphate and the aldehyde group of PL (9) . Additionally, since the degree of disap pearance of the spot corresponding to TOB in the mixture of TOB and PALP seemed to be greater than that in the TOB-PL mixture, it is very likely that the negatively charged phos phate group in PALP also would be involved in the interaction with TOB through, probably, the ionic binding to the positive charge of the protonated amino group of TOB at a very early stage of the interaction.
In the assay of TOB binding to BBMs, PALP added simultaneously with TOB to the membrane fraction significantly inhibited the binding of TOB to BBMs (Fig. 3A) . The lower amount of TOB binding to BBMs observed by the addition of the TOB-PALP mixture suggested that the inhibitory action of PALP on TOB binding to BBMs may be attributed to the molecular interaction be tween TOB and PALP (Fig. 3B) . Moreover, the experiments concerning pretreatment with PALP (except for 0.8 mM of PALP) (Fig.  3B) and TOB binding to the PALP-treated BBMs (Fig. 3D) indicated that even if PALP bound to BBMs, it would not be associated with the inhibition by PALP of the binding of TOB to the membranes.
Additionally, it was evident that the de crease in the inhibitory action of PALP on TOB binding to BBMs was induced by pre incubation of PALP and BBMs not only in the case of the 0.8 mM of PALP but also at other concentrations of PALP (Fig. 4A) . The de crease in the capability of PALP to inhibit the TOB binding to BBMs, which was observed in Fig. 4B and C, suggests a contribution of PALP existing outside, but not inside, of the BBM vesicles to the inhibition of TOB binding to B B M s.
Moreover, the inability of PL to suppress the TOB binding to BBMs suggests the im portance of the negatively charged phosphate group of PALP in inhibiting the binding of TOB to the membranes. The evidence that PN and 4-PA, which did not show an obvious interaction with TOB, were ineffective in in hibiting the TOB binding to BBMs also may imply a possible involvement of the interac tion between PALP and TOB in the inhibition by PALP of the binding of TOB to BBMs. In addition, we confirmed by thin layer chroma tography the interaction of TOB with PALP which occurred during the incubation process (data not shown). Thus, the results of the binding assay indicate that PALP inhibits the binding of TOB to BBMs and that the inhib itory action of PALP is due to the interaction of PALP and TOB outside of BBM vesicles.
In our study, we found that PALP treatment significantly inhibited the intrarenal TOB con centration (Fig. 5A ). This result was in agree ment with the observation reported by Kacew (10), using gentamicin and PALP. It has been shown that spermine, a polyamine, reduced the gentamicin uptake in the rat kidney cortex (11) and that the binding of gentamicin to rat BBMs was inhibited by spermine (12) . These observations suggested that reduction of intrarenal gentamicin level was associated with the inhibition of gentamicin binding to BBMs. Thus, the suppression by PALP of the intrarenal TOB level may result from the inhib ition of TOB binding to BBMs by PALP.
Moreover, we found the similar inhibitory rate of intrarenal TOB concentration by PALP in the each combination of TOB and PALP (Fig. 5B) and the limited administration time of PALP to suppress the renal accumulation of TOB (Fig. 5C ). These observations suggest that the reduced TOB level in the kidney may be due to the interaction of both compounds which leads to less binding of TOB to BBMs, rather than due to the physiological action of PALP in the kidney. The existence of a com plex of polyamine and PALP in urine (13) may strengthen the above possibility, al though in this study, the detection of a TOB PALP complex in vivo was not attempted.
Finally, in the in vivo nephrotoxicity study, we demonstrated that PALP prevented the development of nephrotoxicity induced by TOB, as elucidated by the biochemical (Fig.  6 ) and histological (Fig. 7) observations.
Because it has been suggested that the level of aminoglycoside antibiotics (AGs) in the kidney is related to the degree of the nephrotoxicity of AGs (14) (and indeed, we also confirmed a positive correlation between the suppression rate of the intrarenal TOB level by PALP and the degree of suppression by PALP of BUN and plasma creatinine levels elevated by TOB (data not shown)), the pro tective action of PALP against TOB-induced nephrotoxicity may be due to reduction of the intrarenal concentration of TOB by PALP.
However, recently, it has been suggested that the binding of AGs with biomembranes and liposomal membranes, which leads to alterations in several membrane functions (15) (16) (17) (18) (19) , plays an important role in the pathogenesis of AGs-induced nephrotoxicity. Williams et al. (20) have proposed the signifi cance of the binding affinity of AGs to BBMs in the toxic action of AGs on rat kidneys. Thus, our finding that PALP inhibited the binding of TOB to BBMs also may be included in the explanation of the mechanism of the protec tive action of PALP against TOB nephro toxicity.
In conclusion, the results of the present study indicate that PALP obviously protects rat kidneys from nephrotoxicity induced by TOB and that the protective action of PALP against the nephrotoxicity of TOB may be due to the reduction in intrarenal TOB concen tration and the inhibition of the binding of TOB to BBMs. Additionally, the interaction of TOB and PALP may, at least in part, play a role in the protective effect of PALP against TOB nephrotoxicity.
